BELLUS Health Receives Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough Patients

BELLUS Health ((TSX:BLU) has announced that the US Food and Drug Administration (FDA) has accepted Bellus’ investigational new drug (IND)...

BELLUS Health Closes $35M Financing to Support Development of its Lead Drug Candidate BLU-5937 for Chronic Cough

BELLUS Health (TSX:BLU) a clinical-stage biopharmaceutical company, today announced that it has closed an equity offering, issuing a total of...